본문 바로가기
KERD
논문KCI 등재

경직장전립선 생검환자에서 감염 합병증

Infection in Patients Undergoing Transrectal Ultrasound Guided Prostate Biopsy

정승일
대한요로생식기감염학회|2013.04|Urogenital Tract Infection|제8권 제1호|pp. 20-26

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

InfectionBiopsyProstateAntibiotic prophylaxis
주제분류비뇨기과학

초록

With the widespread popularity of prostate specific antigen testing, transrectal ultrasound (TRUS)-guided prostate biopsy has become a common urological procedure. The most common risks and complications associated with TRUS-guided biopsy include hematuria, hematospermia, and hematochezia. In addition, some patients develop urinary tract infections, acute bacterial prostatitis, bacteremia, and, eventually, urosepsis. Although it is commonly accepted that use of a prophylactic antimicrobial agent will lower the incidence of post biopsy infection, there is little consensus regarding the most appropriate antimicrobial regimens. Fluoroquinolone (FQ) was the best analyzed class, with higher numbers of studies and patients. According to recent data, occurrence of infectious complications after prostate biopsy has increased in recent years. Several recent studies have highlighted an increasing trend of infectious complications due to FQ resistant organisms among men undergoing TRUS guided prostate biopsy. TRUS guided prostate biopsy can result in significant morbidity, which is occurring at an increasing rate due to the increasing prevalence of FQ resistant Escherichia coli in rectal flora. Risk factors for harboring FQ resistant E. coli should be considered before prostate biopsy, and rectal swab screening cultures may provide useful evidence for selection of appropriate antimicrobials for prophylaxis and treatment of prostate biopsy-associated infections. The estimate of the incidence of sepsis following TRUS-guided prostate biopsy is low; however, the initial treatment of patients with prophylaxis failure and identification of antibiotic-resistant bacterial strains might be the most important means for prevention of urosepsis.

Abstract

With the widespread popularity of prostate specific antigen testing, transrectal ultrasound (TRUS)-guided prostate biopsy has become a common urological procedure. The most common risks and complications associated with TRUS-guided biopsy include hematuria, hematospermia, and hematochezia. In addition, some patients develop urinary tract infections, acute bacterial prostatitis, bacteremia, and, eventually, urosepsis. Although it is commonly accepted that use of a prophylactic antimicrobial agent will lower the incidence of post biopsy infection, there is little consensus regarding the most appropriate antimicrobial regimens. Fluoroquinolone (FQ) was the best analyzed class, with higher numbers of studies and patients. According to recent data, occurrence of infectious complications after prostate biopsy has increased in recent years. Several recent studies have highlighted an increasing trend of infectious complications due to FQ resistant organisms among men undergoing TRUS guided prostate biopsy. TRUS guided prostate biopsy can result in significant morbidity, which is occurring at an increasing rate due to the increasing prevalence of FQ resistant Escherichia coli in rectal flora. Risk factors for harboring FQ resistant E. coli should be considered before prostate biopsy, and rectal swab screening cultures may provide useful evidence for selection of appropriate antimicrobials for prophylaxis and treatment of prostate biopsy-associated infections. The estimate of the incidence of sepsis following TRUS-guided prostate biopsy is low; however, the initial treatment of patients with prophylaxis failure and identification of antibiotic-resistant bacterial strains might be the most important means for prevention of urosepsis.

참고문헌 (42)

  1. Chun FK, "Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature", Eur Urol, 58, pp.851~864 (2010)
  2. Nam RK, "Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy", J Urol, 183, pp.963~968 (2010)
  3. Pinkhasov GI, "Complications following prostate needle biopsy requiring hospital admission or emergency department visits - experience from 1000 consecutive cases", BJU Int, 110, pp.369~374 (2012)
  4. Carignan A, "Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis?", Eur Urol, 62, pp.453~459 (2012)
  5. Feliciano J, "The incidence of fluoroquinolone resistant infections after prostate biopsy--are fluoroquinolones still effective prophylaxis?", J Urol, 179, pp.952~955 (2008)
  6. Bootsma AM, "Antibiotic prophylaxis in urologic procedures: a systematic review", Eur Urol, 54, pp.1270~1286 (2008)
  7. Wagenlehner FME, "Infective complications after prostate biopsy: outcome of the global prevalence of infections in urology (GPIU) prostate biopsy side study 2010-a multinational, multicenter study", Eur Urol Suppl, 11, pp.E37~U362 (2012)
  8. Loeb S, "Complications after prostate biopsy: data from SEER-Medicare", J Urol, 186, pp.1830~1834 (2011)
  9. Loeb S, "Infectious complications and hospital admissions after prostate biopsy in a European randomized trial", Eur Urol, 61, pp.1110~1114 (2012)
  10. Wagenlehner FM, "GPIU investigators. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study", Eur Urol, 63, pp.521~527 (2013)
  11. Enlund AL, "Morbidity of ultrasound-guided transrectal core biopsy of the prostate without prophylactic antibiotic therapy. A prospective study in 415 cases", Br J Urol, 79, pp.777~780 (1997)
  12. Larsson P, "Antibiotic prophylaxis for prostate biopsy: benefits and costs", Prostate Cancer Prostatic Dis, 2, pp.88~90 (1999)
  13. Puig J, "Transrectal ultrasound-guided prostate biopsy: is antibiotic prophylaxis necessary?", Eur Radiol, 16, pp.939~943 (2006)
  14. Kapoor DA, "Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy", Urology, 52, pp.552~558 (1998)
  15. Sabbagh R, "A prospective randomized trial of 1-day versus 3-day antibiotic prophylaxis for transrectal ultrasound guided prostate biopsy", Can J Urol, 11, pp.2216~2219 (2004)
  16. Schaeffer AJ, "Comparison of a 3-day with a 1-day regimen of an extended-release formulation of ciprofloxacin as antimicrobial prophylaxis for patients undergoing transrectal needle biopsy of the prostate", BJU Int, 100, pp.51~57 (2007)
  17. Aron M, "Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study", BJU Int, 85, pp.682~685 (2000)
  18. Lindstedt S, "Single-dose antibiotic prophylaxis in core prostate biopsy: Impact of timing and identification of risk factors", Eur Urol, 50, pp.832~837 (2006)
  19. Briffaux R, "Short or long schemes of antibiotic prophylaxis for prostate biopsy. A multicentre prospective randomised study", Prog Urol, 19, pp.39~46 (2009)
  20. Naber KG., "Which fluoroquinolones are suitable for the treatment of urinary tract infections?", Int J Antimicrob Agents, 17, pp.331~341 (2001)
  21. Grabe M., "Antibiotic prophylaxis in urological surgery, a European viewpoint", Int J Antimicrob Agents, 38 Suppl, pp.58~63 (2011)
  22. Grabe M, "Preoperative assessment of the patient and risk factors for infectious complications and tentative classification of surgical field contamination of urological procedures", World J Urol, 30, pp.39~50 (2012)
  23. Zani EL, "Antibiotic prophylaxis for transrectal prostate biopsy", Cochrane Database Syst Rev, (5), pp.CD006576~ (2011)
  24. Aus G, "Infection after transrectal core biopsies of the prostate--risk factors and antibiotic prophylaxis", Br J Urol, 77, pp.851~855 (1996)
  25. Ozden E, "Incidence of acute prostatitis caused by extended- spectrum beta-lactamase-producing Escherichia coli after transrectal prostate biopsy", Urology, 74, pp.119~123 (2009)
  26. Loeb S, "Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare", J Urol, 189, pp.867~870 (2013)
  27. Steensels D, "Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound- guided prostate biopsy--should we reassess our practices for antibiotic prophylaxis?", Clin Microbiol Infect, 18, pp.575~581 (2012)
  28. Abughosh Z, "A prospective randomized trial of povidone-iodine prophylactic cleansing of the rectum before transrectal ultrasound guided prostate biopsy", J Urol, 189, pp.1326~1331 (2013)
  29. Batura D, "Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy", BJU Int, 106, pp.1017~1020 (2010)
  30. Liss MA, "Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy", J Urol, 185, pp.1283~1288 (2011)
  31. Minamida S, "Prevalence of fluoroquinolone-resistant Escherichia coli before and incidence of acute bacterial prostatitis after prostate biopsy", Urology, 78, pp.1235~1239 (2011)
  32. Duplessis CA, "Rectal cultures before transrectal ultrasound- guided prostate biopsy reduce post-prostatic biopsy infection rates", Urology, 79, pp.556~561 (2012)
  33. Taylor AK, "Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care", J Urol, 187, pp.1275~1279 (2012)
  34. Wagenlehner F, "Influence of a prophylactic single dose of ciprofloxacin on the level of resistance of Escherichia coli to fluoroquinolones in urology", Int J Antimicrob Agents, 15, pp.207~211 (2000)
  35. Williamson DA, "Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen", Clin Infect Dis, 54, pp.1406~1412 (2012)
  36. Kehinde EO, "Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate", J Urol, 189, pp.911~915 (2013)
  37. Adibi M, "Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis", J Urol, 189, pp.535~540 (2013)
  38. Adibi M, "Cost-effectiveness of standard vs intensive antibiotic regimens for transrectal ultrasonography (TRUS)-guided prostate biopsy prophylaxis", BJU Int, 110, pp.E86~91 (2012)
  39. Ekici S, "Fluoroquinolone-resistant acute prostatitis requiring hospitalization after transrectal prostate biopsy : effect of previous fluoroquinolone use as prophylaxis or long-term treatment", Int Urol Nephrol, 44, pp.19~27 (2012)
  40. Miura T, "Levofloxacin resistant Escherichia coli sepsis following an ultrasound-guided transrectal prostate biopsy: report of four cases and review of the literature", Int J Urol, 15, pp.457~459 (2008)
  41. 신보성, "경직장초음파 유도하 전립선 생검 후 ciprofloxacin 내성균에 의한 세균혈증의 임상 특성", 대한요로생식기감염학회지, 6(1), pp.61~66 (2011), 대한요로생식기감염학회
  42. Siriboon S, "Prevalence of antibiotic resistance in fecal flora of patients undergoing transrectal ultrasound-guided prostate biopsy in Thailand", Urol Int, 88, pp.187~193 (2012)

관련 논문AI추천

경직장초음파 유도하 전립선 생검 후 ciprofloxacin 내성균에 의한 세균혈증의 임상 특성권동득, 김진웅, 류수방, 박광성, 신보성, 정승일, 황의창대한요로생식기감염학회 · Urogenital Tract Infection2011 · 제6권 제1호Infectious Complications after Prostate Biopsy: A Prospective Multicenter Prostate Biopsy Study정홍, 권동득, 김광현, 김기호, 김영호, 김태형, 김태환, 김태효, 나용길, 민승기, 박성운, 박흥재, 배상락, 심봉석, 양승옥, 양승우, 유호송, 윤하나, 이길호, 이동현, 이상돈, 이서연, 이선주, 이승주, 임동훈, 장인호, 정승일, 정재민, 조용현, 조원열, 조원진, 최현섭, 하유신, 한준현, 한창희, 허정식, 황의창, 대한요로생식기감염학회대한요로생식기감염학회 · Urogenital Tract Infection2016 · 제11권 제1호경직장초음파하 전립선조직검사 후 발생한 발열을 동반한 요로감염의 위험인자김영주, 김현주, 허정식대한요로생식기감염학회 · Urogenital Tract Infection2012 · 제7권 제1호단일 술자에 의해 외래에서 시행된 경직장초음파하 전립선침생검 후 Betadine 거즈 압박이 입원을 요하는 합병증의 발생에 미치는 영향정홍, 김홍섭, 양상국대한요로생식기감염학회 · Urogenital Tract Infection2012 · 제7권 제1호Optimal Modified Extended Antibiotic Prophylaxis for Prostate Biopsy: The Addition of Two Intravenous Doses of Amikacin to Ciprofloxacin권동득, 정승일, Ho Seok Chung, Myung Soo Kim, Seong Hyeon Yu대한요로생식기감염학회 · Urogenital Tract Infection2018 · 제13권 제3호Changes of Antimicrobial Resistance Causing Infections Following Transrectal Prostate Biopsy: Analysis of 10-Year DataDa Eun Han, Du Geon Moon, Hong Seok Park, Jong Wook Kim, Mi Mi Oh, Sun Tae Ahn대한요로생식기감염학회 · Urogenital Tract Infection2021 · 제16권 제3호

이 간행물의 다른 논문 (11건)

한국인의 급성 세균성 전립선염의 특성박승철pp. 1-6만성전립선염의 유발 및 악화 인자정홍pp. 7-12무증상전립선염의 임상적 의미와 치료조인창, 민승기pp. 13-19술 전 무균뇨 환자에서 경요도전립선 수술 후 감염합병증의 위험인자박광성, 정승일, 권동득, 강택원, 황의창, 유성현, 김종범pp. 27-31대한민국 40-50대 남성에서 만성전립선염 증상 정도가 조루증에 미치는 영향김유석, 조인창, 김성빈, 민승기pp. 32-37
원문 보기